Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

no longer respond to the standard of care under Fast Track designation from the U.S. Food and Drug Administration.

About Carcinoid Syndrome

Carcinoid syndrome is a chronic condition caused by metastatic neuroendocrine tumors that usually originate from the gastrointestinal tract. These tumors secrete large amounts of serotonin, which can cause a variety of symptoms including severe diarrhea and abdominal discomfort. Patients with carcinoid syndrome currently have limited therapeutic options, and the standard of care includes chronic therapy with somatostatin analogues, which are delivered by injection. With current therapy, the gastrointestinal symptoms return over time in the vast majority of patients, hence the need for new agents.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1032 and the potential therapeutic and commercial potential of LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and ... 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy ... Santa Ana division (the "Bankruptcy Court") on ... to be jointly administered. The Company will evaluate ... for all or substantially all of its assets to a ...
(Date:3/3/2015)... Cambridge Semantics, the leading provider of smart ... that it has been named to KMWorld’s 2015 list ... , To create the list each year, KMWorld ... integrators who identify organizations dedicated to the true value ... the right people at the right time. , ...
(Date:3/3/2015)...  Johnson & Johnson Innovation LLC today announced the ... (JLABS @SSF), a 30,000-square foot incubator located at ... Calif. The Johnson & Johnson Innovation, JLABS ... across the healthcare spectrum including biotech, pharmaceutical, medical device, ... resident startups have been selected, including the winners of ...
(Date:3/3/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announced it has initiated commissioning activities for its 30,000 ... Sarnia, Ontario , Canada.  Commissioning ... with the facility being in commercial operation in Q3 ... two months and it is carrying out commissioning and ...
Breaking Biology Technology:AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
... YORK , June 11 The Champalimaud Foundation, ... that Dr. J. Anthony Movshon , Director of ... William T. Newsome , Investigator at The Howard Hughes ... , are the recipients of its 2010 Vision Award.  The ...
... Genomic Health, Inc. (Nasdaq: GHDX ) today announced the ... of Clinical Oncology (ASCO) Annual Meeting, including an evaluation of ... cancer, suggesting a potential role for the Onco typ e ... pending further study. The company also announced the first presentation ...
... , June 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... will host a conference call and webcast on Monday, June 7th, 2010 ... discuss the Phase I/II head and neck cancer data being presented that day ... , , ...
Cached Biology Technology:Prestigious International Champalimaud Vision Award to US Scientists 2Prestigious International Champalimaud Vision Award to US Scientists 3Prestigious International Champalimaud Vision Award to US Scientists 4Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 9Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting 2Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting 3
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... ISRAEL, August 9, 2010 Ben-Gurion University of the Negev ... Samuel and Paula Elkeles Prize for Outstanding Scientist in the ... the Shraga Segal Department of Microbiology and Immunology and vice ... of Health Sciences. He is also the Irving Sklar ...
... is available in German . , Spectroscopic techniques ... look inside materials. They exploit the interaction of light waves ... spectroscopy, researchers from Helmholtz-Zentrum Berlin fr Materialien und Energie (HZB) ... solvent so-called electron transfer. They can even make assertions ...
... of Case Western Reserve University School of Medicine, has ... Pioneer Award. One of 17 awardees to ... genetic effects, where the biological features and disease risk ... much on the genetics of ancestral generations as on ...
Cached Biology News:Ben-Gurion University of the Negev professor awarded the 2010 Elkeles Prize for Cancer Research 2Help from the dark side 2Case Western Reserve geneticist receives prestigious NIH Director's Pioneer Award 2
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Laminin beta-1/gamma-1 (612C10)...
... choice of Printing Surface (3 glass slides coated with ... 1 silicon wafer coated with 1000 Angstroms of Gold ... PDMS Stamps (3 PDMS micropatterned stamps with series of ... 10 mm or 200 um x 10 mm lines, ...
X box-binding protein 1...
Biology Products: